Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06593548 | Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer | not yet recruiting | Phase 2 | 36 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06594211 | Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma | not yet recruiting | N/A | 18 | RenJi HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06594432 | Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement | not yet recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06594471 | Comprehensive Assessment of Clinical Characteristics and Outcomes of Gemelli Adolescents and Young Adults(G-AYA) | not yet recruiting | — | 500 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06594692 | Node-Sparing Short-Course Radiation With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: A Randomized, Prospective, Multicenter Study(mRCAT-C) | not yet recruiting | Phase 2 | 140 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06594874 | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors | not yet recruiting | Phase 1 | 350 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06596343 | Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 80 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06598917 | Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRT | not yet recruiting | Phase 2 | 60 | China Medical University HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06598969 | TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia(TMLI-MA) | not yet recruiting | Phase 2 | 58 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06599775 | Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer | not yet recruiting | Phase 2 | 42 | Shanghai Zhongshan HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06599801 | Clinical Outcomes of Thoracodorsal Artery Flap in Oral and Maxillofacial Reconstruction | not yet recruiting | — | 217 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06599827 | Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC(iMHRT-LARC) | not yet recruiting | Phase 2 | 54 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06600503 | The Effect of a Mobile Application on Enhancing Pulmonary Rehabilitation After Lung Cancer Surgery | not yet recruiting | N/A | 36 | National Cheng Kung UniversityOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06600841 | Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer | not yet recruiting | Phase 2 | 37 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06602323 | TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.(TMLI-RI) | not yet recruiting | Phase 2 | 34 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06602661 | Reinforced and Non-Reinforced Staple Lines in Fissureless Lobectomy | not yet recruiting | Phase 1 | 65 | Surrey Thoracic Surgery GroupOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06602986 | Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma | not yet recruiting | N/A | 96 | Pak Emirates Military HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06603974 | The Efficacy and Safety of Benmelstobart for GC/EGC(EASOBFGE) | not yet recruiting | N/A | 48 | Xijing HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06604351 | Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction(Example) | not yet recruiting | Phase 2 | 39 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06585059 | Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers | not yet recruiting | Phase 1 | 20 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 5, 2024 | clinicaltrials |
| NCT06585644 | A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC | not yet recruiting | Phase 2 | 44 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT06578871 | Surgery and Reducing Ionizing Radiation of the Unknown Primary(SUPERIOR) | not yet recruiting | Phase 2 | 90 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Sep 3, 2024 | clinicaltrials |
| NCT06581380 | JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 394 | JenKem Technology Co., Ltd.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT06582108 | UNDERSTANDING the RAREST GYNECOLOGICAL CANCERS: a MULTI -OMICS PLATFORM for IMPROVED PATIENTS MANAGEMENT(ROAR) | not yet recruiting | — | 190 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06258018 | Niraparib and Temozolomide in Patients Glioblastoma(ONC-2022-001) | not yet recruiting | Phase 1 / Phase 2 | 86 | Armando Santoro, MDOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT06483009 | Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC | not yet recruiting | Phase 4 | 20 | Shanghai Chest HospitalOTHER | 0 | Aug 30, 2024 | clinicaltrials |
| NCT06576362 | Evaluation of Ultrasound-guided Transuterine Vaginal Biopsy Technique in Uterine Fibromatous Disease(EFIBIA) | not yet recruiting | N/A | 250 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Aug 30, 2024 | clinicaltrials |
| NCT06580665 | Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer | not yet recruiting | N/A | 134 | Shanghai Chest HospitalOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT06577961 | Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients | not yet recruiting | Phase 1 / Phase 2 | 37 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT06578286 | ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | not yet recruiting | Phase 2 | 44 | Fudan UniversityOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT06578299 | Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer | not yet recruiting | Phase 4 | 100 | Fudan UniversityOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT06574412 | Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma. | not yet recruiting | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 0 | Aug 28, 2024 | clinicaltrials |
| NCT06556680 | EB-OCT Biopsy Guidance of Lung Cancer | not yet recruiting | N/A | 200 | Massachusetts General HospitalOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06571461 | Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer | not yet recruiting | Phase 3 | 408 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06572592 | The Predictive Value of MRI for Adult-type Diffuse Gliomas(MRI; glioma;) | not yet recruiting | — | 200 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06573099 | A Real-World Study on Extranodal Lymphoma | not yet recruiting | — | 5,000 | Ruijin HospitalOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06573138 | Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL | not yet recruiting | Phase 2 | 18 | Ruijin HospitalOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06573151 | Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL | not yet recruiting | Phase 2 | 28 | Ruijin HospitalOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06573398 | Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC | not yet recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06573645 | A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL | not yet recruiting | Phase 3 | 428 | Xia YiOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06567756 | Conformal Sphincter-Preservation Operation Versus InterSphincteric Resection on Anal Function in Low Rectal Cancer | not yet recruiting | N/A | 84 | Changhai HospitalOTHER | 0 | Aug 23, 2024 | clinicaltrials |
| NCT06039956 | De-escalating Axillary Surgery in Breast Cancer Patients in Nigeria | not yet recruiting | N/A | 100 | Nova Scotia Health AuthorityOTHER | 0 | Aug 22, 2024 | clinicaltrials |
| NCT06470841 | CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML | not yet recruiting | Phase 2 | 85 | Navy General Hospital, BeijingOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06563050 | Comparison Between Different Ways for Using Lidocaine During FB | not yet recruiting | N/A | 240 | Assiut UniversityOTHER | 0 | Aug 22, 2024 | clinicaltrials |
| NCT06567600 | Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 43 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04933422 | CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) | not yet recruiting | Phase 1 | 72 | Crimson Biopharm Inc.INDUSTRY | 0 | Aug 21, 2024 | clinicaltrials |
| NCT06434493 | Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma(EMPHATIC) | not yet recruiting | N/A | 30 | The Christie NHS Foundation TrustOTHER | 0 | Aug 21, 2024 | clinicaltrials |
| NCT06557304 | The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China | not yet recruiting | — | 1,000 | Peking University People's HospitalOTHER | 0 | Aug 21, 2024 | clinicaltrials |
| NCT06563934 | Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs) | not yet recruiting | Phase 2 | 70 | Xu Yong, MDOTHER | 0 | Aug 21, 2024 | clinicaltrials |
| NCT06321016 | POZIKIDS: Exercise and Comprehensive Care to Improve the Quality of Life of Children and Adolescents With Cancer(PoziKids) | not yet recruiting | N/A | 45 | Nere MendizabalOTHER_GOV | 0 | Aug 20, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Sep 19, 2024source: clinicaltrials